The aim of this study is to investigate the effects of spironolactone on liver fibrosis
progression and portal pressure gradient in patients with advanced chronic liver disease.
Eligible cirrhosis patients were 2:1 randomized to either combination (carvedilol and
spironolactone) or single (carvedilol) therapy group. Changes in virtual portal pressure
gradient (vPPG) of portal trunk (calculated based on reconstructed 3D model and measured
blood flow velocity), liver stiffness measurement (Fibroscan) and serum markers of liver
fibrogenesis were documented at baseline and six months later.